BMS bets on ADC potential with $3.1bn Eisai partnership

Retrieved on: 2021-06-22 09:11:15

Tags for this article:

Click the tags to see associated articles and topics

BMS bets on ADC potential with $3.1bn Eisai partnership. View article details on hiswai:

Excerpt

In terms of how Eisai manages the manufacturing process, a spokesperson told BioPharma-Reporter that “currently, the production of MORAb-202 as ...

Article found on: www.biopharma-reporter.com